Literature DB >> 26260711

Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study.

Fariba Ahmadizar1, Soulmaz Fazeli Farsani1, Patrick C Souverein1, Marja Mj van der Vorst2, Anthonius de Boer1, Anke H Maitland-van der Zee1.   

Abstract

OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents.
METHODS: Children and adolescents (<19 yr) with T1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort study between 1999 and 2009. The date of first insulin dispensing was selected as the index date.
RESULTS: The overall prevalence rate of cardiovascular medication use was substantially higher in the T1D cohort before (2.2 vs. 1.0%, p < 0.001) and after (9.2 vs. 3.2%, p < 0.001) the index date. After the index date angiotensin-converting enzyme inhibitors (2.0%) and statins (1.5%) were the most prevalent cardiovascular medications in the T1D cohort. The highest incidence rate of cardiovascular medication use was observed in the first year after the index date [28.1 per 1000 person years (PY)]. Furthermore, three type 1 diabetic patients were hospitalized due to cardiomyopathy (n = 2) and heart failure (n = 1) and one child from the reference group was hospitalized due to cardiomyopathy in the 5 yr after the index date.
CONCLUSIONS: Children with T1D were more likely to use cardiovascular medications in the years before and after the onset of diabetes. Our study emphasizes the importance of routine screening tests and timely treatment of CVD risk factors in the pediatric population with diabetes.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiovascular; children; incidence; prevalence; type 1 diabetes

Mesh:

Substances:

Year:  2015        PMID: 26260711     DOI: 10.1111/pedi.12302

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  4 in total

1.  AdDIT Editorial comment-challenges in medication treatment of renal and cardiovascular diseases and risk factors in adolescents with type 1 diabetes.

Authors:  Fariba Ahmadizar; Anke H Maitland-van der Zee
Journal:  Ann Transl Med       Date:  2018-05

2.  Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use.

Authors:  Fariba Ahmadizar; Patrick Souverein; Anthonius de Boer; Anke H Maitland-van der Zee
Journal:  Br J Clin Pharmacol       Date:  2018-01-25       Impact factor: 4.335

3.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 4.  Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events?

Authors:  Evgenia Gourgari; Dana Dabelea; Kristina Rother
Journal:  Curr Diab Rep       Date:  2017-11-03       Impact factor: 4.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.